Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$20.50 ▼ -0.06
(-0.29%)
MKT CAP: $400.8M • VOL: 139.6K
52W L $16 52W H $40
ROARABLE / RQD
D- • 37/100
PIOTROSKI
2 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$17
MEDIAN
$23
MEAN
$23
HIGH
$28
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE TECX TAPE
TECX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $24.80 | $23.57 | 2025-02-14 | $18.66 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $25.83 | $24.19 | 2025-02-06 | $19.27 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $23.37 | $22.55 | 2025-01-29 | $19.68 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $20.91 | — | 2025-01-17 | $20.09 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $18.04 | $19.47 | 2025-01-09 | $18.25 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $24.39 | $21.32 | 2024-12-18 | $17.84 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $19.88 | $20.71 | 2024-12-04 | $19.07 | -4.3% | 48% | C |